Newsroom
William Morice II, M.D., Ph.D., highlights data-driven reasons health systems benefit from the lab service line and strategies to bolster performance.
William Morice II, M.D., Ph.D. shares how platform business models support the shift to more holistic, patient-centered care.
Mary Jo Williamson, chief administrative officer of Mayo Clinic Laboratories, shares four critical steps for successful healthcare collaborations.
On Tuesday, June 24, the mayocliniclabs.com website will feature a refreshed homepage. Incorporating valuable feedback from users, the site has been redesigned it to highlight the most frequently used features and content. The aim to enhance user experience with a more intuitive, visually appealing, and responsive website. These new features will make it easier to find information and complete tasks.
Dr. Morice joins Becker’s Healthcare to discuss how a platform approach to diagnostics and strategic collaborations enhances outcomes.
Medical Laboratory Professionals Week is a time to appreciate the profound impact of laboratory medicine on healthcare and innovation.
Mayo Clinic Laboratories and Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, today announced a collaboration to expand access to Amprion's SAAmplify–αSYN (CSF) test across the United States. The test (test ID ASYNC) is available today for clients of Mayo Clinic Laboratories through the collaboration that combines the expertise of both organizations to enhance patient care and improve diagnostic accuracy for neurodegenerative diseases.
Mayo Clinic Laboratories and KYAN Technologies announced a collaboration to validate and provide the KYAN test, Optim.AI™, across the United States.
In a Fierce Healthcare article, Dr. William Morice highlights AI, digital pathology, and mass spectrometry as key advancements revolutionizing healthcare diagnostics and treatment.
Mary Jo Williamson, chief administrative officer of Mayo Clinic Laboratories, shares insights on balancing needs with future-oriented investments.
Mayo Clinic Laboratories’ guidance for subtyping influenza A in response to a CDC advisory for hospitalized patients
The healthcare and diagnostics landscape is poised for transformative changes driven by technological advancements and evolving market dynamics.
Mayo Clinic Laboratories and Lucence are expanding access to advanced cancer testing worldwide with LiquidHALLMARK®, a next-generation liquid biopsy that provides actionable genomic insights. This collaboration empowers physicians to deliver personalized care and improve patient outcomes.